Takara Bio Third Quarter 2025 Earnings: Misses Expectations

Takara Bio (TSE:4974) Third Quarter 2025 Results

Key Financial Results

• Revenue: JP¥9.52b (down 10% from 3Q 2024).
• Net loss: JP¥1.89b (loss widened by 103% from 3Q 2024).
• JP¥15.70 loss per share (further deteriorated from JP¥7.72 loss in 3Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Takara Bio Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 162%.

Looking ahead, revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Japan.

Performance of the Japanese Biotechs industry.

The company's shares are down 10% from a week ago.

Risk Analysis

You should learn about the 1 warning sign we've spotted with Takara Bio.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.